Royal Capital Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Royal Capital Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	+500	New	+$222K	0.14%	83
2024 Q3	–	Sell	-429	Closed	-$201K	–	98
2024 Q2	$201K	Buy	+429	New	+$186K	0.15%	88
2024 Q1	–	Sell	-1,002	Closed	-$408K	–	99
2023 Q4	$408K	Sell	1,002 -15	-1%	-$5.54K	0.35%	53
2023 Q3	$354K	Sell	1,017 -38	-4%	-$13.3K	0.34%	56
2023 Q2	$371K	Hold	1,055	–	–	0.35%	56
2023 Q1	$332K	Sell	1,055 -24	-2%	-$7.2K	0.33%	63
2022 Q4	$312K	Hold	1,079	–	–	0.33%	62
2022 Q3	$312K	Hold	1,079	–	–	0.36%	62
2022 Q2	$304K	Hold	1,079	–	–	0.33%	67
2022 Q1	$282K	Sell	1,079 -6	-0.6%	-$1.42K	0.28%	79
2021 Q4	$238K	Buy	+1,085	New	+$211K	0.23%	88

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Royal Capital Wealth Management's VRTX Position: Q2 2026 in Review

Royal Capital Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 500 shares worth $248K. The stake represents 0.14% of the portfolio and ranks #83 among its holdings. This is a return to the name: Royal Capital Wealth Management previously reported a position in VRTX as recently as Q2 2024.

Royal Capital Wealth Management first reported a position in VRTX in Q4 2021 and has held it in 11 quarters since. The position peaked at $408K in Q4 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Royal Capital Wealth Management held 500 shares of Vertex Pharmaceuticals worth $248K as of Q2 2026.
Vertex Pharmaceuticals was a new Royal Capital Wealth Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.14% of Royal Capital Wealth Management's portfolio in Q2 2026, its #83 holding.
Royal Capital Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Royal Capital Wealth Management's Vertex Pharmaceuticals position peaked at $408K in Q4 2023.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Royal Capital Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.